ZIMMER BIOMET HOLDINGS, INC.
ZBHNYSEHealthcare · Orthopedic, Prosthetic & Surgical Appliances & Supplies · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $8.23B | $7.68B | $7.39B | $6.94B | $7.84B | $7.02B |
| Operating income | $1.10B | $1.29B | $1.28B | $696.3M | $780.1M | −$87.8M |
| Net income | $705.1M | $903.8M | $1.02B | $231.4M | $401.6M | −$138.9M |
| Total assets | $23.09B | $21.37B | $21.50B | $21.07B | $23.46B | $24.42B |
| Total liabilities | $10.39B | $8.89B | $9.01B | $9.04B | $10.79B | $12.22B |
| Equity | $12.70B | $12.47B | $12.48B | $12.02B | $12.66B | $12.19B |
| EPS (diluted) | $3.55 | $4.43 | $4.88 | $1.10 | $1.91 | $-0.67 |
| Shares out. | 199.1M | 205.1M | 209.0M | 209.2M | 207.9M | 206.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 13.3%
- Net margin
- 8.6%
- Return on equity
- 5.6%
- Return on assets
- 3.1%
- Return on capital (ROCE)
- 5.4%
- Liabilities / assets
- 45.0%
- Debt / equity
- 0.82×
- Book value / share
- $63.79
- Revenue growth (YoY)
- 7.2%
- Net income growth (YoY)
- −22.0%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 3.96safe
- Accruals / assets
- −4.3%clean
- Beneish M-Score
- -2.57normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 6 good- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Price T Rowe Associates Inc /Md/Passive (13G)May 15, 2026
- Vanguard Capital Management LlcPassive (13G)Apr 30, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Harris Associates L PPassive (13G)Feb 17, 2026
- Dodge & CoxPassive (13G)Aug 13, 2025
- Blackrock, Inc.Passive (13G)Apr 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 9.2M | 4.1 | -8.3% |
| Apr 30, 2026 | 10.0M | 3.2 | -0.9% |
| Apr 15, 2026 | 10.1M | 5.1 | +0.8% |
| Mar 31, 2026 | 10.0M | 5.1 | +24.8% |
| Mar 13, 2026 | 8.0M | 3.6 | +4.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 27, 2026
- Regulation FD disclosureMay 12, 2026
- Director / officer change · Regulation FD disclosureApr 28, 2026
- Results of operationsApr 28, 2026
- Results of operationsFeb 10, 2026
- Director / officer changeJan 12, 2026
- Results of operationsNov 5, 2025
- Other material eventOct 7, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Corporate family
Spun off from Bristol-Myers SquibbBMY · Aug 6, 2001
Spin-offs from ZIMMER BIOMET HOLDINGS, INC. (1)
- ZimVie Inc.ZIMVcompletedFeb 2, 2022details
From the spin-off filings we track. Follow a company to walk its own history.